Neuropsychiatric symptoms in untreated Parkinson’s disease

Szabolcs Szatmari1–3
Ben Min-Woo Illigens4
Timo Siepmann5,6
Alexandra Pinter5,7
Annamaria Takats8
Daniel Bereczki8

1Department of Neurology, Sibiu County Emergency Hospital, Sibiu, 2nd Department of Neurology, Targu Mures Emergency Clinical County Hospital, Targu Mures, Romania; 3János Szentágothai Doctoral School of Neurosciences, Semmelweis University, Budapest, Hungary; 4Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 5Center for Clinical Research and Education, Division of Health Care Sciences, Dresden International University, 6Department of Neurology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; 7Department of Family Medicine, 8Department of Neurology, Semmelweis University, Budapest, Hungary

Correspondence: Timo Siepmann
Department of Neurology, University Hospital Carl Gustav Carus, Technical University of Dresden, 74 Fetscher Street, 01307 Dresden, Germany
Tel +49 351 458 3565
Fax +49 351 458 4365
Email timo.siepmann@uniklinikum-dresden.de

Abstract: Neuropsychiatric and cognitive symptoms are common in Parkinson’s disease (PD) and may precede and exceed motor symptoms as major factors impacting disease course and quality of life. Neuropsychiatric symptoms (NPS) in PD are various and are attributed to pathologic changes within multiple brain regions, to psychological stress, and to adverse effects of dopamine replacement therapy. Sleep disorders and mood symptoms such as apathy, depression, and anxiety may antedate the development of motor symptoms by years, while other NPS such as impulse control disorders, psychosis, and cognitive impairment are more common in later stages of the disease. Few studies report on NPS in the early, untreated phase of PD. We reviewed the current literature on NPS in PD with a focus on the early, drug-naïve stages of PD. Among these early disease stages, premotor and early motor phases were separately addressed in our review, highlighting the underlying pathophysiological mechanisms as well as epidemiological characteristics, clinical features, risk factors, and available techniques of clinical assessment.

Keywords: neuropsychiatric symptoms, Parkinson’s disease, untreated

Introduction

In Parkinson’s disease (PD), in addition to the typical motor symptoms, nonmotor symptoms (NMS) may occur, neuropsychiatric manifestations often being the most common.1 The premotor phase in PD is dominated by different NMS that are known to have a major impact throughout the course of the disease. A number of clinical subtypes with differing NMS patterns have been established, which feature the early, untreated phase of the disease. This framework ensures that NMS are more readily identified and treated optimally. The phenotypic variants are as follows: park cognitive (predominantly presents with cognitive impairment at an early stage), park apathy (high scores on apathy scales), park depression/anxiety (early manifestation of these symptoms), park sleep (characterized by excessive daytime sleepiness or rapid eye movement behavior disorder), park pain (different pain syndromes dominate the clinical picture), park fatigue (exhibited as an independent and severe symptom), and park autonomic (gastrointestinal, genitourinary symptom dominant, and adrenergic dysfunction dominant) subtypes.2 A recent study found that the prevalence of neuropsychiatric symptoms (NPS) in early, untreated PD patients was up to 56%.3 Several prior studies have shown these symptoms to have an adverse impact on patient’s everyday activities, quality of life, as well as the burden of their caregivers and the health services.4–12 Previous research has also suggested that these symptoms are frequently unrecognized and untreated due to several factors such as the incomplete understanding of mental health problems, illness-specific concerns among patients,
Apathy in untreated PD

Apathy can be defined as a behavioral disturbance of primary loss of motivation that is not attributable to reduced intellectual impairment, emotional distress, or level of consciousness.22 The underlying mechanism of apathy in PD patients is unclear. Positive correlation was found between apathy scores and cerebral metabolism in the inferior/middle frontal gyrus, cuneus, and the insula,23 and there is evidence that apathy in PD is associated with reduced gray matter density in several brain regions such as the precentral gyrus, the inferior parietal gyrus, the inferior frontal gyrus, and the insula.24 It has also been described that apathy is associated with reduced striatal dopamine transporter levels, independent of depression, suggesting that disruption of dopaminergic innervation in the right caudate nucleus and striatum may contribute to the development of apathy even in early, untreated PD with motor disability already present.25 Moreover, recent findings suggest that combined dopaminergic and serotonergic degeneration, especially within the caudate nucleus, could be a key mechanism underlying apathy in newly diagnosed, untreated PD patients with motor symptoms.26 Therefore, such results underline the fact that the pathogenesis of this symptom is complex and is not exclusively linked to dopaminergic dysfunction.

The prevalence of apathy in patients with PD ranges from 17% to 50% overall.27–30 The wide range of the reported prevalence values may be attributable to differences between study design, disease severity, and the methods used to detect apathy. Apathy has been identified in untreated, newly diagnosed PD patients with motor symptoms, where the prevalence ranged between 12% and 33%31,32 however, such cohorts have not been extensively studied in this regard. Studies show that after excluding patients with depression or dementia, the prevalence of apathy in PD drops to 3%–11%,33–36 suggesting that symptom overlaps are important to consider.

A case–control, multicenter study – the ONSET PD study – has shown that apathy can precede the onset of motor symptoms in drug-naive PD subjects at early stages, the prevalence being 50%.37 In addition, a retrospective study that used interviews performed by telephone found
the frequency of apathy to be 23.7% in the prodromal untreated phase of PD.38

The assessment of apathy is difficult because of overlaps with depressive symptoms and cognitive impairment;39,40 nevertheless, there is evidence confirming that apathy in PD also commonly occurs as an independent symptom.41 A recent study validated the apathy evaluation scale (AES) as a reliable questionnaire for detecting apathy in PD.32

Apathy should be taken into consideration already in the early phases of PD because it has been associated with reduced quality of life in patients,42 increased caregiver burden,43,44 altered social relationships,45 low cognitive status,46 increased motor symptoms, and more severe disability.47-50 Furthermore, it can easily remain undetected, unless specifically screened for. Therefore, early and accurate identification, especially in untreated, newly diagnosed PD patients, can contribute to optimal clinical management.

Depression in untreated PD

Depression is defined as a low mood state as indicated by feelings of sadness, despair, anxiety, emptiness, discouragement or hopelessness, and aversion to activity that can affect a person’s thoughts or feelings, behavior, and sense of well-being.51

Neurobiological factors associated with the underlying neurodegenerative processes in PD play an important role in the appearance of depressive symptoms and may not represent a reaction to disability only.52 Several studies have analyzed the neuroanatomical background of depression in PD, mainly with neuroimaging techniques. These publications report that depressive symptoms in PD are related to decreased hippocampus and amygdala volume53,54 and increased brain metabolism in the amygdala.55 Bilateral decreases in regional cerebral blood flow of the medial prefrontal cortex is also a common finding in PD patients with depression.56 Abnormal functional connectivity of the amygdala, the prefrontal-limbic system, the prefrontal cortex, and the lingual gyrus was associated with depressive symptoms in PD patients;57,58 however, a study found intact limbic-prefrontal connections54 in a similar group of patients. Furthermore, depression in PD is also related to gray and white matter volume deterioration in the orbitofrontal and temporal regions as well as in the cortical-limbic system.59-61 Changes in neuronal systems that are associated with the regulation of mood disturbances, such as dopaminergic, noradrenergic, and serotonergic systems, in limbic and cortical structures might also be involved,62 but the exact pathomechanism is yet unknown. Furthermore, depression can manifest as a mood reaction to PD itself and to the progressive disability. In summary, depressive symptoms in PD can have various etiologies. Interestingly, depression can appear several years before the onset of motor manifestations and use of DRT.37 The strong link between depression and PD is underlined by the increased likelihood of developing PD in a cohort of patients with depression than in controls; therefore, it may also be an independent risk factor for PD.37,18,63-66

Depression is one of the most frequently reported NPS in PD generally;67 prevalence varies depending on the diagnostic approach (major or minor depressive disorder and dysthymia), the evaluation of patients, and the study population used. A meta-analysis calculated the prevalence of depression in PD overall, taking into account the different settings and different approaches to diagnosis. The weighted prevalence of clinically significant depression in PD was 35%, more precisely of major depressive disorder was 17%, that of minor depression was 22%, and that of dysthymia was 13%.67

A study which assessed the impact of depression in the early, untreated stages of PD with motor symptoms already present found a prevalence rate of 27.6%.68 Studies involving untreated PD patients showed that, of the NMS, depressed mood was more frequent 2 years and even 10 years before motor onset, the prevalence being 23.7%–68%37,38

General risk factors for depression in PD include motor disability,69 longer duration of the disease,70 predominance of right-sided motor symptoms,71 akinetic-rigid variant of PD,72 presence of other NPS,73,74 restless legs syndrome (RLS),75 presence of sleep disorders,76,77 higher daily doses of levodopa,78 younger age,78 and female gender.79

Since depression in PD has been associated with poorer quality of life and increased caregiver concern,68,80,81 it is essential to adequately screen for and correctly treat depression already at the onset of PD. Depressive symptoms are frequently masked by other NPS and motor disturbances, and it can develop at any phase in the course of PD;8 therefore, it is difficult to recognize it. For screening, the fourth edition of the DSM-IV diagnostic criteria for major depression, minor depression, and dysthymia in PD has been validated.53 Still, one of the greatest challenges in PD remains diagnosing and treating depressive symptoms to the point of remission.

Anxiety in untreated PD

Generalized anxiety disorder (GAD) is characterized by excessive worry and anxiety that are difficult to control, cause significant impairment and distress, and occur on >50% of the days within at least 6 months.51 GAD in PD is characterized by excessive worry about disease progression, muscle...
tension, or everyday worries such as financial concerns. Social phobia in PD is described as fear of social consequences resulting from PD symptoms manifesting in public.83

The exact pathomechanism of anxiety is still unclear; however, dysfunction in the dopaminergic system might be implicated, even in newly diagnosed, never treated PD patients.84–86 Tissue reduction in the amygdala and bilateral decreased metabolism in the caudate nucleus may also contribute to the development of anxiety.55,87 These symptoms could precede the onset of motor symptoms by as much as 20 years and may be early manifestations during the prodromal phase of PD.18,66 In addition, the risk of developing PD was found to be greater in a population with anxiety and correlated with the severity of anxiety according to a recent study.88 Moreover, the psychological reaction to the development of motor disturbances should not be neglected.

Anxiety is a common NMS among patients with PD overall, with a prevalence interval between 34% and 65%, GAD being the most frequently diagnosed condition.89–91 Other common anxiety disorders described in PD are panic attacks and social phobias.92

In two PD cohorts of drug-naive subjects with motor symptoms, the prevalence of anxiety (16.4% and 24.6%) was also higher than in non-PD controls.3,93 A study examined anxiety in the premotor phase of untreated PD and found a prevalence of 13.3%.38

To assess the severity of anxiety symptoms, several scales are used (eg, State-Trait Anxiety Inventory); however, none of these meet the criteria to be recommended and are classified only as suggested.94

Risk factors and predictors reported for anxiety symptoms in patients with PD in general include young-onset PD, higher rates of motor fluctuations, morning dystonia,92 severity of PD, postural instability, gait dysfunction, symptom clustering and experience of dyskinesia,95 nontremor-dominant motor subtype, depressive symptoms, worst sleep quality, being nonwhite, female gender, and younger age.93,96,97

Similar to other NPS, anxiety symptoms in PD also have a negative impact on the quality of life;98 therefore, its timely recognition and adequate treatment are of paramount importance.

ICDs in untreated PD

ICDs are a class of psychiatric disorders characterized by impulsivity, failure to resist a temptation, urge, or impulse that may harm oneself or others.91 The clinical spectrum of ICDs is extensive; the primary disorders in PD include pathological gambling, compulsive shopping, hyperphagia, hypersexuality, and punding, as well as compulsive use of dopaminergic medication with consequent dopamine dysregulation syndrome (DDS).20,99,100 The occurrence of ICD has been associated with overstimulation of the mesolimbic system by dopamine treatment.101–103 Decreases in the binding potential of a dopaminergic tracer in the ventral striatum have been reported in PD patients with pathological gambling phenomena undergoing DRT.104 In addition, another study of PD gamblers showed a disconnection between the anterior cingulate cortex and the striatum.105 Furthermore, the development of ICD is somewhat related to a significant loss of gray matter volume in the frontal lobe.106 In drug-naive PD patients with motor symptoms, who later on develop ICD, lower baseline dopamine transporter availability in the right ventral striatum, anterior-dorsal striatum, and posterior putamen has been shown.107

The association between high doses of dopaminergic medications, particularly dopamine agonists and increased risk to develop ICDs, seems evident;20,109,110 however, currently available literature deals with PD patients undergoing DRT only. The prevalence of ICDs and related behaviors in treated PD was found to be ranging from 8.1% to 43%,20,111,112 With motor symptoms already present, recent data suggest that the frequency of ICD symptoms is as common in patients with early-stage, drug-naive PD as in healthy controls;113,114 the prevalence ranging between 17.5% and 18.5%. As far as we know, the prevalence of ICD in newly diagnosed, untreated PD in the premotor stage has not been studied so far.

The development of these behaviors in general is significantly associated with younger onset of PD, male gender, smoking,111,115,116 comorbid psychiatric symptoms and greater functional impairment in PD,117 personal or family history of gambling, and solitary marital status;20 however, the main risk factor for developing impulsive behaviors remains the DRT.

For early detection and screening of ICD, the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) has been recently developed and validated, which appears to be a very sensitive instrument for this particular behavioral disorder assessment.118,119

Taken together, findings so far suggest that ICDs are frequent in PD even before the initiation of dopaminergic medication and they are as common as in healthy controls. Therefore, factors other than PD itself lead to the occurrence of ICDs. Careful identification and active screening of...
predictive factors and symptoms are needed; moreover, close follow-up on the behavioral alterations to DRT of patients is needed, as these are not automatically reported to physicians. Besides, treatment is challenging and complex as patients may experience dopamine agonist withdrawal syndrome, hence minimizing this complication is very advisable.

Psychosis in untreated PD

Psychosis is a condition of the mind broadly defined as a loss of contact with reality. Psychotic symptoms in PD include delusions and hallucinations, which are risk factors for dementia and predictors of poor prognosis, mortality, and nursing home placement. In addition, it has been identified as a significant determinant of caregiver burden.

Based on previous studies, hallucinations are mainly associated with dopaminergic agent use (especially dopaminergic agonists, amantadine, and monoamine oxidase B inhibitors). In addition, in PD, persistent visual hallucinations have been linked to high densities of Lewy bodies in the amygdala and parahippocampus and have been shown to be associated with dysfunction of the temporal lobe, frontal lobe cingulate cortex, hippocampus, primary and secondary visual cortex, thalamus, precuneus, and cerebellum. Concerning the neural pathways, there is evidence, which indicates that serotonin may also contribute to the pathogenesis of complex visual hallucinations besides dopamine in PD, via involvement of the serotonin 2 receptor. Historical descriptions of PD from the prelevodopa era suggest that hallucinations may be part of PD itself, especially in the context of depression or dementia.

Visual hallucinations are present in about one-quarter to one-third of PD patients overall, auditory being as much as 20%. Sense of presence and visual illusions affect 17%–72% of the patients, and delusions affect ~5%. Nevertheless, in the early stages of PD with motor symptoms, minor hallucinatory phenomena (presence hallucinations, passage hallucinations, and visual hallucinations) have been described in up to 30% of patients. In other studies, psychotic symptoms were very rare in patients with early-stage, untreated PD. A very recent study analyzing incident PD patients, already in the premotor untreated phase, also confirmed the hypothesis that the use of dopaminergic drugs is not mandatory for hallucinations to appear in PD, and 33.3% of patients with minor hallucinations manifested these as a premotor symptom; however, the confirmation of these results is necessary.

The main nonmodifiable risk factor of psychosis is cognitive impairment. Other associated factors include older age/longer duration of PD, disease severity, presence of daytime somnolence or rapid eye movement (REM) sleep behavior disorders (RBDs), depression, and dysautonomia.

Since psychotic symptoms are not always reported voluntarily by patients, clinicians should always ask for such experiences. There are some rating scales in use, but none of them are widely accepted. The Neuropsychiatric Inventory and item 2 of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) subscale 1 can be used for screening. More detailed assessments can be made using specific scales such as Parkinson Psychosis Rating Scale. An MDS Task Force recently reviewed psychosis rating scales used in PD and listed the “recommended” ones for use in PD.

Despite the association between medication exposure and psychosis in PD, the duration and dosage of DRT do not clearly correlate with psychosis; furthermore, based on the previous debating results mentioned, the etiology of psychosis in PD is complex and needs further investigation. In the early, untreated stages in PD, although psychosis is less frequent than in more advanced disease, better understanding of these phenomena is needed, which will lead to better care and improved quality of life.

Sleep disorders in untreated PD

The most frequent sleep disorders in PD are insomnia, excessive daytime sleepiness, RLS, and RBD. The causes of sleep disturbances are multifactorial, but damage to several brainstem nuclei that are directly involved in the regulation of sleeping mechanisms, which are affected in very early premotor stages of PD, is probably significant. Nigrostriatal dopaminergic degeneration could also play a role in the pathogenesis of RBD but not essential for its development. Abnormalities in primary sleep-regulating centers, some NMS have secondary effect on the quality of sleep, such as nocturia, RLS, and narcoleptic pattern of rapid onset of sleep, which are also important causes of sleep-related morbidity in PD. As causative factors, besides the neurodegenerative processes within sleep regulatory brain circuitries, DRT and concomitant medications (eg, antidepressants) as well as comorbidities or other NMS (such as depression) are proposed. Sleep-related problems are also reported to increase the risk of development of PD in the later life similarly to anxiety disorders and depression.

or RLS, and because they usually precede the classic motor abnormalities of PD by many years, they should be clinically evaluated as a potential marker for PD before its onset. Similarly, sleep dysfunctions occur in untreated PD.
PD as well.15,16 These facts suggest that the condition is likely to be related to the underlying dopaminergic deficit rather than the effect of dopaminergic treatment, which seems to be only an aggravating component.

In general, sleep disorders affect up to 75% of patients with PD.15 Other studies that have evaluated the prevalence of the various sleep disorders in PD patients reported a wide range of prevalence because of different methods used and different PD stage examinations.157–163 A recent study exploring the distribution of sleep quality in untreated PD patients with motor symptoms found that 59.2% of the patients had sleep disturbances and the percentage was even higher in patients treated with DRT.164 In premotor untreated PD, according to studies, the prevalence of sleep disturbances was 17%–52%.165

The presence of sleep problems in PD predicts more NMS, fatigue, depression, and cognitive decline,159 and as other NPS, they have a significant negative impact on patients’ quality of life.165

For the diagnosis of sleep disturbances, the recommended and validated regular screening questionnaires are as follows: the Pittsburgh Sleep Quality Index (PSQI) and the Medical Outcomes Study (MOS) Sleep Scale; for evaluating daytime sleepiness, the recommended and validated regular screening questionnaires are as follows: the Epworth Sleepiness Scale (ESS), the Inappropriate Sleep Composite Score (ISCS), and the Stanford Sleepiness Scale (SSS).164 The Parkinson’s Disease Sleep Scale (PDSS) has also been validated166,167 as a simple screening tool for identifying the various types of nocturnal disabilities that disrupt sleep in PD.

Summing up, sleep disorders often precede the development of motor symptoms in PD. Close follow-up of patients with idiopathic sleep disorders could enable early detection of PD.

**Cognitive impairment in untreated PD**

Findings from prior studies suggest that initial cognitive decline in PD is triggered by comorbid pathology that occurs with aging, widespread PD pathology, or early diffuse brainstem pathology.168–172

The rate of cognitive decline in the premotor phase of PD compared to controls is similar based on two population-based studies,173,174 suggesting that global cognitive dysfunction may not occur in premotor PD. Generally, in PD, ~25% of nondemented patients have mild cognitive impairment (MCI)175 and up to 80% of all PD patients will eventually develop dementia.176 Prior studies have shown that a representative rate (10%–40%) of new, untreated PD patients with motor symptoms have cognitive deficits.93,177–179 This wide range might be attributed to many factors including study design, methodology, and definition for MCI in PD. The prevalences of cognitive deficits in the two studies with patients in the premotor untreated phase of PD were as follows: memory complaints 54%, inattention 60%, problems to recall words 32.4%, bradyphrenia 25.8%, and forgetfulness 41.9%.37,38

Patients with PD and cognitive decline have more severe dysfunction in the domains of executive and visuospatial functioning and attention, with lesser involvement of memory and language.180

Based on preliminary studies, cognitive decline is predicted by older age, male gender, being nonwhite, lower educational level, worse olfaction, more severe motor symptoms, presence of RBD symptoms, and other NPS at baseline.93,181–184 Cognition in PD is assessed using the Parkinson’s Disease-Cognitive Rating Scale and the Mattis Dementia Rating Scale-2, but there are several other scales, which can be used with the same purpose.185,186

**Treatment of PD and its correlation with NPS**

Although the mechanisms whereby primary NPS related to PD and NPS related to antiparkinsonian medication affect each other are not fully understood, clinical observations underscore the importance of an optimal personalized clinical management in these patients. In general, patients with dopaminergic therapy are more likely to be bad sleepers, depressed, and with cognitive impairment compared to untreated patients.164,187,188 In addition, initiation of DRT is associated with an increase in ICD symptoms, psychosis, and excessive daytime sleepiness. However, a summary of several clinical trials on the effects of DRT in PD suggested therapeutic benefit regarding NPS, mainly depression and anxiety.15 Practically, the introduction of DRT does not significantly improve most of these symptoms because the majority of NPS does not worsen extensively in the first years of PD regardless of treatment. This may suggest that the neuropsychiatric burden and cognitive deficits in newly diagnosed, untreated PD patients are not high overall compared to more advanced, treatment-influenced disease stages.

**Discussion/conclusion**

Current data suggest that PD should not be considered as a motor disorder only. In addition to the motor symptoms, the prevalence of NPS in PD is high even in the early, untreated
phases of the disease and is associated with reduced quality of life of patients, increased disability, greater caregiver burden, and higher treatment costs. The most frequent NPS in the untreated phase of PD are those of depression, cognitive impairment, and sleep disturbances. The high heterogeneity of PD and the current descriptions of specific NMS-dominant phenotypes in the early, untreated phase of the disease support the idea of nonmotor subtyping. This may be challenging as PD subtypes are unlikely to be apparent, and there is considerable possibility that these subtypes will overlap throughout the course of the disease and are likely to be present only in a proportion of patients. Identification of such subtypes may ensure that NMS are not missed and may have important implications on the development of subtype-specific therapies. It is still unclear to what extent the etiology of NPS is a result of psychosocial stress factors, the neurodegenerative process of PD itself, or complications of DRT. It seems evident that NPS in PD are most likely multifactorial in origin, the contribution of these factors may differ across disease stages and it is highly influenced by DRT. Several but not all NPS are more common in untreated, newly diagnosed patients with PD compared to the general population, but they also remain relatively stable in the early stages of the disease. In contrast, initiation of DRT and disease progression is associated with increasing frequency of several NPS (Table 1). The prevalence and onset of NPS relative to the manifestation of first PD motor symptoms are not well characterized. Assessing the onset of NPS and NMS in general in the premotor phase is difficult because few patients can report them with sufficient precision. It is usually difficult for subjects to remember whether they had some specific symptoms. Therefore, data cannot be assumed to be entirely exact in this regard. It is uncertain to what extent NPS and cognitive impairment are the result of the widely distributed neurodegenerative process itself, psychological and clinical factors, or the complication of DRT. Undeniably, the contribution of each factor is probable resulting from a number of simultaneous processes throughout the course of the disease. The early and routine screening for a range of prevalent NPS and their related factors is important to initiate optimal treatment. Therefore, close collaboration and a multidisciplinary, personalized care are needed for the effective treatment of patients with PD. Relatively little is known about the clinical course and prognostic significance of NPS and cognitive impairment in PD; therefore, further studies are needed to better understand NPS and cognition in PD soon after the diagnosis and before DRT introduction.

**Acknowledgments**

DB was supported by the National Brain Research Program of the Government of Hungary, no KTIA-NAP-13-2013-001. TS has received grants from the Michael J. Fox Foundation, the European Academy of Neurology, and Prothena Biosciences that were not related to this work. SS has received a grant from the Society of Transylvanian Museum – Section of Medicine and Pharmacy to support his work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(4):492–496.
2. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(suppl 1):S41–S46.
3. Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928–930.
4. Taylor AE, Saint-Cyr JA. Depression in Parkinson’s disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci. 1990;2(1):92–98.
5. Weintraub D. Neuropsychiatric symptoms in Parkinson disease and dementia with Lewy bodies: what geriatric psychiatry can learn. Am J Geriatr Psychiatry. 2013;21(6):497–500.
6. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry. 2005;13(10):844–851.
7. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52(5):784–788.
8. Marsh L, Berk A. Neuropsychiatric aspects of Parkinson’s disease: recent advances. Curr Psychiatry Rep. 2003;5(1):68–76.
9. Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17(1):60–67.
10. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–312.

**Table 1 Reported prevalence of NPS in various phases of PD**

| NPS                      | Overall in PD (%) | Untreated premotor phase of PD (%) | Untreated motor phase of PD (%) |
|--------------------------|-------------------|-----------------------------------|----------------------------------|
| Apathy                   | 17–50             | 24–50                             | 12–30                            |
| Depression               | 35                | 24–68                             | 28                               |
| Anxiety                  | 34–65             | 13                                | 16–25                            |
| ICD                      | 8–43              | No data                           | 17–18                            |
| Psychosis                | 17–72             | 33                                | 30                               |
| Sleep disturbances       | 75                | 17–52                             | 59                               |
| Cognitive impairment     | 25–80             | 26–60                             | 10–40                            |

**Abbreviations:** ICD, impulse control disorder; NPS, neuropsychiatric symptoms; PD, Parkinson’s disease.
55. Huang C, Radvin LD, Nirenberg MJ, et al. Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an [18F]fusor-deoxyglucose positron emission computed tomography study. *Dement Geriatr Cogn Disord*. 2013;35(3–4):183–196.

56. Ring HA, Bench CJ, Trimbille MR, Brooks DJ, Frackowiak RS, Dolan RJ. Depression in Parkinson’s disease: a positron emission study. *Br J Psychiatry*. 1994;165(3):333–339.

57. Sheng K, Fang W, Su M, et al. Altered spontaneous brain activity in patients with Parkinson’s disease accompanied by depressive symptoms, as revealed by regional homogeneity and functional connectivity in the prefrontal-limbic system. *PLoS One*. 2014;9(1):e84705.

58. Hu X, Song X, Yuan Y, et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson disease. *Mov Disord*. 2015;30(2):238–244.

59. Feldmann A, Illes Z, Kosztolanyi P, et al. Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. *Mov Disord*. 2008;23(1):42–46.

60. Kostić VS, Agosta F, Petrović I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. *Neurology*. 2010;75(10):857–863.

61. Matsui H, Nishinaka K, Oda M, et al. Depression in Parkinson’s disease. Diffusion tensor imaging study. *J Neurol*. 2007;254(9):1170–1173.

62. Aarsland D, Pahlhagen S, Ballard CG, Ehr U, Svenningsson P. Depression in Parkinson disease – epidemiology, mechanisms and management. *Nat Rev Neurol*. 2011;8(1):35–47.

63. Shen CC, Tsai SJ, Peng CL, Kuo BI, Yang AC. Risk of Parkinson disease after depression: a nationwide population-based study. *Neurology*. 2013;81(17):1538–1544.

64. Fang F, Xu Q, Park Y, et al. Depression and the subsequent risk of Parkinson’s disease in the NIH-AARP Diet and Health Study. *Mov Disord*. 2010;25(9):1157–1162.

65. Schuurman AG, van den Akker M, Ensink KT, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. *Neurology*. 2002;58(10):1501–1504.

66. Jacob EL, Gatto NM, Thompson A, Bordelon Y, Ritz B. Occurrence of depression and anxiety prior to Parkinson’s disease. *Parkinsonism Relat Disord*. 2010;16(9):576–581.

67. Rejinders JS, Ehr U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. *Mov Disord*. 2008;23(2):183–189. quiz 313.

68. Ravina B, Camicioli R,Compo PG, et al. The impact of depressive symptoms in early Parkinson disease. *Neurology*. 2007;69(4):342–347.

69. Riedel O, Kotsche J, Spottek A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. *J Neurol*. 2010;257(7):1073–1082.

70. Wichowicz HM, Slawek J, Derejko M, Cubala WJ. Factors associated with depression in Parkinson’s disease: a cross-sectional study in a Polish population. *Eur Psychiatry*. 2006;21(8):516–520.

71. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. *J Nerv Ment Dis*. 1990;178(1):27–31.

72. Starkstein SE, Petracca G, Chemerinski E, et al. Depression in classic Parkinson’s disease. *Parkinsonism Relat Disord*. 1998;13(1):29–33.

73. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. *Neurology*. 2004;63(2):293–300.

74. Chen JJ, Marsh L. Depression in Parkinson’s disease: identification and management. *Pharmacotherapy*. 2013;33(9):972–983.

75. Krishnan PR, Bhattacharjee B, Behar M. Restless leg syndrome in Parkinson’s disease: a case-controlled study. *Mov Disord*. 2003;18(2):181–185.

76. Tandberg E, Larsen JP, Karlsten K. A community-based study of sleep disorders in patients with Parkinson’s disease. *Mov Disord*. 1998;13(6):895–899.

77. Happé S, Berger K. FAQT Study Investigators. The association between caregiver burden and sleep disturbances in partners of patients with Parkinson’s disease. *Age Ageing*. 2002;31(5):349–354.

78. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. *Arch Neurol*. 1997;54(5):625–630.

79. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson’s disease: clinical correlates and outcome. *Parkinsonism Relat Disord*. 2003;10(1):23–28.

80. Muller B, Assmus J, Herloffson K, Larsen JP, Tynnes OB. Importance of non-motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. *Parkinson Relat Disord*. 2013;19(11):1027–1032.

81. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. *J Neurol Neurosurg Psychiatry*. 1992;55(5):377–382.

82. Starkstein SE, Merello M, Jorge P, et al. A validation study of depressive syndromes in Parkinson’s disease. *Mov Disord*. 2008;23(4):538–546.

83. Aarsland D, Taylor JP, Weintraub D. Psychiatric issues in cognitive impairment. *Mov Disord*. 2014;29(5):651–662.

84. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. *J Nucl Med*. 2005;46(2):227–232.

85. Moriyama TS, Felicio AC, Chagas MH, et al. Increased dopamine transporter density in Parkinson’s disease patients with Social Anxiety Disorder. *J Neurol Sci*. 2011;310(1–2):53–57.

86. Erro R, Pappata S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. *Parkinsonism Relat Disord*. 2012;18(9):1034–1038.

87. Vriend C, Boedhoe PS, Rutten S, Berendse HW, van der Werf YD, van den Heuvel OA. A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. *J Neurol Neurosurg Psychiatry*. 2016;87(5):493–500.

88. Lin CH, Lin JW, Liu YC, Chang CH, Wu RM. Risk of Parkinson’s disease following anxiety disorders: a nationwide population-based cohort study. *Eur J Neurol*. 2015;22(9):1280–1287.

89. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. *Mov Disord*. 2011;26(3):484–492.

90. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. *Parkinsonism Relat Disord*. 2015;21(6):629–634.

91. Rutten S, Ihlelen I, Vriend C, et al. Anxiety in Parkinson’s disease: symptom dimensions and overlap with depression and autonomic failure. *Parkinsonism Relat Disord*. 2015;21(3):189–193.

92. Pontone GM, Williams JR, Anderton KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. *Mov Disord*. 2009;24(9):1333–1338.

93. Weintraub D, Simuni T, Cappell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. *Mov Disord*. 2015;30(7):919–927.

94. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a French cross-sectionnal DoPaMiP study. *Parkinsonism Relat Disord*. 2015;21(6):803–809.

95. Negre-Pages L, Grandjean H, Lapeyre-Mestre M, et al; DoPaMiP Study Group. Importance of anxiety-related subtypes in Parkinson’s disease. *Mov Disord*. 2015;30(7):919–927.
824

99. Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol. 2011;24(4):324–330.

100. Vilas D, Pont-Sunyer C, Tolosa E. Impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(suppl 1): S80–S84.

101. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F]dopa metabolism in the striatum in Parkinson’s disease. Brain. 1996;119(pt 6): 2097–2103.

102. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia. 2003;41(11): 1431–1441.

103. Braak H, Ghebremedhin E, Rub U, Bratze K, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318(1):121–134.

104. Steeves TD, Miyasaki J, Christos PJ, Nirenberg MJ. Prospective association with impulse control disorders in Parkinson’s disease. Mov Disord. 1999;132(pt 6):1376–1385.

105. Cilia R, Cho SS, van Eimeren T, et al. Pathological gambling in patients with Parkinson’s disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord. 2011;26(2):225–233.

106. Biundo R, Formento-Dojot P, Fanchini S, et al. Brain volume changes in Parkinson’s disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci. 2011;310(1–2):64–69.

107. Friend C, Nordbeck AH, Booj J, et al. Reduced dopamine transporter binding predicts impulse control disorders in Parkinson’s disease. Mov Disord. 2014;29(7):904–911.

108. Balrajaj A, Cavanaugh AE. The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol. 2013;26(4):237–244.

109. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopaminergic agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969–973.

110. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease. Mov Disord. 2011;26(3):464–468.

111. Callesen MB, Weintraub D, Damholt MD, Moller A. Impulsive and compulsive behaviors among Danish patients with Parkinson’s disease: prevalence, depression, and personality. Parkinsonism Relat Disord. 2014;20(1):22–26.

112. Weintraub D, Papay K, Siderowf A; Parkinson’s Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;80(2):176–180.

113. Antonini A, Sieri C, Santangelo G, et al. Impulsivity and compulsivity in drug-naive patients with Parkinson’s disease. Mov Disord. 2011;26(4):986–996.

114. Valenza GT, Glass PG, Negreiros NS, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(7):698–700.

115. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–333.

116. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case – control study. Ann Neurol. 2011;69(6):986–996.

117. Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461–1467.

118. Probst CC, Winter LM, Moller B, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol. 2014;261(5):936–942.

119. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.

120. Cunningham AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(9): 1051–1052.

121. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):12–17.

122. Goetz CG, Fan W, Leurgans S, Bernard B, Stobbins GT. The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol. 2006;63(5):713–716.

123. Goetz CG, Stobbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology. 1995;45(4):669–671.

124. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–138.

125. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605–610.

126. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391–403.

127. Shin S, Lee JE, Hong JY, Sunwoo MK, Sohn YH, Lee PH. Neuro-anatomical substrates of visual hallucinations in patients with non-demented Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83(12):1155–1161.

128. Oishi N, Udaoka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65(11):1708–1715.

129. Gama RL, Bruin VM, Tavora DG, Duran FL, Bittencourt L, Tufik S. Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn. 2014;87:97–103.

130. Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson’s disease with FDG PET. Mov Disord. 2004;19(7):801–806.

131. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Brain response to complex visual stimuli in Parkinson’s patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord. 2008;23(16):2335–2343.

132. Watanabe H, Senda J, Kato S, et al. Cortical and subcortical brain atrophy in Parkinson’s disease with visual hallucination. Mov Disord. 2013;28(12):1732–1736.

133. Pagonabarraga J, Soriano-Mas C, Llebaria G, Lopez-Sola M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(3):290–296.

134. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67(4):416–421.

135. Fenelon G, Soulsas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763–766.

136. Fenelon G, Soulsas T, Cleret de Langavant L, Trinkler I, Bachoud-Levi AC. Feeling of presence in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(11):1219–1224.

137. Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45–52.

138. Morgante L, Colosimo C, Antonini A, et al; PRIAMO Study Group. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83(1):76–82.
141. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov. Disord. 2005;20(11):1439–1448.
142. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov. Disord. 2008;23(4):484–500.
143. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56(5):595–601.
144. Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson’s disease. J Parkinsons Dis. 2014;4(2):211–221.
145. Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci. 2010;289(1–2):81–88.
146. Ianzo A, Molinuovo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5(7):572–577.
147. Kim YK, Yoon IY, Kim JM, et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol. 2010;17(3):487–492.
148. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology. 2002;58(7):1019–1024.
149. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341–346.
150. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442–1446.
151. Postuma RB, Gagnon JF, Montplaisir JY. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(pt 7):1787–1798.
152. Boot BP, Boeve BF, Roberts RO, et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol. 2012;71(1):49–56.
153. Poletti M, Bonuccelli U. Impulse control disorders in Parkinson’s disease patients with mild cognitive impairment and dementia. Neurology. 2007;69(19):1843–1849.
154. Zhang H, Gu Z, An J, Wang C, Chan P. Non-motor symptoms and health-related quality of life in early Parkinson’s disease. Mov. Disord. 2014;29(2):166–168.
155. Martinez-Martin P. Salvador C, Menendez-Guisasola L, et al. Parkinson’s Disease Sleep Scale: validation study of a Spanish version. Mov. Disord. 2004;19(10):1262–1236.
156. Dhawan V, Dhoat S, Williams AJ, et al. The range and nature of sleep disturbances in Parkinson’s disease. J Neurol Sci. 2010;292(1–2):85–92.
157. Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 2007;78(5):476–479.
158. Buskova J, Klempr J, Majerova V, et al. Sleep disturbances in untreated Parkinson’s disease. J Neurol. 2011;258(12):2254–2259.
159. Handa V, Dhoat S, Williams AJ, et al. The range and nature of sleep dysfunction in untreated Parkinson’s disease (PD). A comparative controlled clinical study using the Parkinson’s disease sleep scale and selective polysomnography. J Neurol Sci. 2006;248(1–2):158–162.
160. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005;64(1):81–86.
161. Larsen JP, Tandanberg E. Sleep disorders in patients with Parkinson’s disease: epidemiology and management. CNS Drugs. 2001;15(4):267–275.
162. Prudon B, Duncan GW, Khoo TK, Yarnall AJ, Anderson KN. Primary sleep disorder prevalence in patients with newly diagnosed Parkinson’s disease. Mov. Disord. 2014;29(2):259–262.
163. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry. 2008;79(4):387–391.
164. Zhang H, Gu Z, An J, Wang C, Chan P. Non-motor symptoms in treated and untreated Chinese patients with early Parkinson’s disease. Tohoku J Exp Med. 2014;232(2):129–136.
165. Martinez-Martin P. Nonmotor symptoms and health-related quality of life in early Parkinson’s disease. Mov. Disord. 2014;29(2):166–168.
184. Poletti M, De Rosa A, Bonuccelli U. Affective symptoms and cognitive functions in Parkinson’s disease. *J Neurol Sci*. 2012;317(1–2):97–102.

185. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. *Mov Disord*. 2008;23(7):998–1005.

186. Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson’s disease. *Mov Disord*. 2008;23(11):1546–1550.

187. Barone P, Antonini A, Colosimo C, et al; PRIAMO study Group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. *Mov Disord*. 2009;24(11):1641–1649.

188. Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Lemiëns AF. The role of the dopaminergic system in mood, motivation, and cognition in Parkinson’s disease: a double-blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. *J Neurol Sci*. 2012;320(1–2):121–126.